Forest plots and the interpretation of subgroups [6]

Lancet

Volumn 365, Issue 9467, 2005, Pages 1308-

  Cuzick, Jack ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

CONFIDENCE INTERVAL; HUMAN; LETTER; MEDICAL RESEARCH; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 17044400164     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)61026-4     Document Type: Letter

References (5)

1. J Cuzick The assessment of subgroups in clinical trials M Baum R Kay H Scheurlen Clinical trials in early breast cancer. 2nd Heidelberg Symposium, Heidelberg, Dec 14-17, 1981. Experientia Supplementum 41 1982 224 235
2. R Peto, MC Pike, P Armitage Design and analysis of randomized clinical trials requiring prolonged observation of each patient Br J Cancer 34 1976 585 612
3. The ATAC Trialists' Group Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
4. Early Breast Cancer Trialists' Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials Lancet 351 1998 1451 1467
5. Collaborative Group on Hormonal Factors in Breast Cancer Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies Lancet 347 1996 1713 1727